Skip to content

US · KRRO · BIOTECHNOLOGY

Korro Bio, Inc. (KRRO) intrinsic value and stock valuation

$12.18as of 2026-11-21 · Mkt cap 114.46M

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Korro Bio, Inc. DCF and intrinsic value

InvestorsCraft values KRRO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from KRRO’s statements →

Korro Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02141 korrobio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$6.39M-29.6% 5y CAGRd
20172025
Net income
-$-117.26M
20172025
Free cash flow
-$-79.08M
20172025
Total equity
$51.4M-23.2% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$6.39M$2.27M$0.00$0.00$14.1M
Operating income-$-87.34M-$-91.91M-$-84.53M-$-59M-$-84.03M
Net income-$-117.26M-$-83.58M-$-81.17M-$-58.03M-$-84.69M
EPSd-$-12.47M-$-9.37M-$-53.05M-$-223.19M-$-19.03M
Operating cash flow-$-78.56M-$-60.07M-$-67.28M-$-53.65M-$-32.09M
Capital expenditure-$-520K-$-17.9M-$-7.84M-$-5.21M-$-4.45M
Free cash flow-$-79.08M-$-77.98M-$-75.12M-$-58.86M-$-36.54M
Total assets$113.5M$226.2M$221.7M$73.7M$185.4M
Total debt$43.5M$44.8M$33.2M$167M$45.6M
Net debt$21.7M-$-10.88M-$-132.94M$130.1M-$-34.04M
Total equity$51.4M$160.4M$169.9M-$-99.03M$130.8M
Cash and short-term investments$75.2M$126.1M$166.2M$55.9M$130.7M
Income statement
20252024202320222021
Revenue$6.39M$2.27M$0.00$0.00$14.1M
Cost of revenue$4.28M$0.00$0.00$0.00$3.84M
Gross profit$2.11M$2.27M$0.00$0.00$10.2M
Research and development expenses$65.6M$63.6M$57.3M$42.2M$59.3M
Selling, general and administrative expenses$28.2M$30.6M$36.5M$16.8M$34.9M
Other expenses-$-4.28M$0.00-$-9.25M$0.00$0.00
Operating expenses$89.5M$94.2M$84.5M$59M$94.3M
Cost and expenses$93.7M$94.2M$84.5M$59M$98.1M
Interest income$0.00$0.00$0.00$950K$400K
Interest expense$0.00$0.00$0.00$120K$760K
Depreciation and amortization$4.28M$3.56M$3.63M$2.51M$3.84M
Ebitda-$-83.06M-$-88.34M-$-80.9M-$-56.49M-$-80.07M
Operating income-$-87.34M-$-91.91M-$-84.53M-$-59M-$-84.03M
Total other income/expenses, net-$-29.28M$8.47M$3.39M$980K-$-640K
Income before tax-$-116.62M-$-83.44M-$-81.14M-$-58.02M-$-84.67M
Income tax expense$640K$140K$30K$10K$10K
Net income-$-117.26M-$-83.58M-$-81.17M-$-58.03M-$-84.69M
Weighted average shares outstanding$9.4M$8.92M$1.53M$260K$4.45M
Weighted average diluted shares outstanding$9.4M$8.92M$1.53M$260K$4.45M
Balance sheet
20252024202320222021
Cash and short-term investments$75.2M$126.1M$166.2M$55.9M$130.7M
Net receivables$970K$1.7M$0.00$0.00$140K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$82.4M$131.5M$172.7M$57.1M$134.8M
Property, plant and equipment, net$16.2M$51.6M$42.8M$11.9M$36.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$12.4M$37M$3.41M$4.54M$13.4M
Total non-current assets$31.1M$94.7M$48.9M$16.7M$50.6M
Total assets$113.5M$226.2M$221.7M$73.7M$185.4M
Accounts payable$1.65M$3.99M$7.28M$2.6M$2.75M
Short-term debt$2.67M$1.28M$1.99M$2.92M$2.58M
Deferred revenue$7.83M$3.51M$0.00$0.00$0.00
Total current liabilities$11.9M$15M$19.5M$8.7M$11.4M
Long-term debt$40.8M$43.5M$31.2M$164.1M$43M
Deferred revenue, non-current$7.83M$5.91M$0.00$0.00$0.00
Total non-current liabilities$50.1M$50.9M$32.3M$164.1M$43.1M
Capital lease obligations$43.5M$44.8M$33.2M$210K$28.9M
Total liabilities$62.1M$65.8M$51.8M$172.8M$54.5M
Common stock$10K$10K$10K$0.00$40K
Retained earnings-$-383.85M-$-266.59M-$-183M-$-101.83M-$-180.09M
Accumulated other comprehensive income (loss)$210K$270K-$0.00-$-10K-$-60K
Total equity$51.4M$160.4M$169.9M-$-99.03M$130.8M
Total investments$65.8M$107.4M$3.41M$23.5M$64.5M
Total debt$43.5M$44.8M$33.2M$167M$45.6M
Net debt$21.7M-$-10.88M-$-132.94M$130.1M-$-34.04M
Cash flow statement
20252024202320222021
Net income-$-117.26M-$-83.58M-$-81.17M-$-58.03M-$-21.96M
Depreciation and amortization$3.79M$3.56M$3.63M$2.51M$1.59M
Stock-based compensation$7.66M$4.46M$2.38M$1.14M$810K
Change in working capital-$-4.43M$13.6M$4.28M-$-630K$900K
Accounts receivable$730K-$-1.7M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.31M-$-1.34M$3.1M$1.75M$60K
Net cash provided by operating activities-$-78.56M-$-60.07M-$-67.28M-$-53.65M-$-32.09M
Investments in property, plant and equipment-$-520K-$-17.9M-$-7.84M-$-5.21M-$-4.45M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$44M-$-123.35M$11.2M$11.1M-$-39.5M
Common stock issued$690K$67.4M$117.3M$60K$30K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$690K$69.4M$187.8M$20K$115.9M
Net change in cash-$-33.82M-$-114.07M$131.6M-$-42.57M$44.4M
Cash at end of period$25.2M$59.1M$173.1M$41.5M$84M
Operating cash flow-$-78.56M-$-60.07M-$-67.28M-$-53.65M-$-32.09M
Capital expenditure-$-520K-$-17.9M-$-7.84M-$-5.21M-$-4.45M
Free cash flow-$-79.08M-$-77.98M-$-75.12M-$-58.86M-$-36.54M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Korro Bio, Inc.

        Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

        CEO
        Ram Aiyar
        Employees
        49
        Beta
        2.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Korro Bio, Inc. (KRRO)?

        Korro Bio, Inc. (KRRO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KRRO undervalued?

        KRRO trades at a price of $12.18 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.